Literature DB >> 4029504

Use of a psoralen-induced phenocopy to study genes controlling spermatogenesis in Caenorhabditis elegans.

L G Edgar, D Hirsh.   

Abstract

In the nematode Caenorhabditis elegans, spermatogenesis represents one of two alternative developmental pathways open to premeiotic germ cells. At least two genes, fem-1 and fem-2, control the initiation of spermatogenesis in XX (hermaphrodite) worms, and the entire spectrum of male differentiation in XO animals. Low-dose irradiation of worms treated with the light-activated DNA crosslinking drug trimethylpsoralen, at levels that do not affect cell division or growth rates, blocks spermatogenesis in C. elegans hermaphrodites and produces an identical phenotype to that of temperature-sensitive mutations in the fem genes. Psoralen treatment does not, however, produce corresponding phenotypes of these mutants in XO animals. The developmental age for phenocopy production is the same as the hermaphrodite temperature-sensitive period of the two mutants. The effects of pulses of restrictive temperature and psoralen treatment on fem-2 mutant hermaphrodites are additive, suggesting that psoralen crosslinking may reduce the level of the fem-2 gene product. Microbeam experiments localize the target for the psoralen effect to the primary germ cells in the first stage larvae, indicating that a critical step occurs in a small number of precursor cells prior to their commitment to spermatogenesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029504     DOI: 10.1016/0012-1606(85)90439-7

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  2 in total

1.  Inhibition of Caenorhabditis elegans vulval induction by gap-1 and by let-23 receptor tyrosine kinase.

Authors:  A Hajnal; C W Whitfield; S K Kim
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

2.  The C.elegans MAPK phosphatase LIP-1 is required for the G(2)/M meiotic arrest of developing oocytes.

Authors:  Alex Hajnal; Thomas Berset
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.